Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

By afschroeder • September 6, 2026

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West RM, Pillai P, Marinello P, Herrera AF. Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study. Blood Neoplasia. 2026 May 26;3(4):100252. doi: 10.1016/j.bneo.2026.100252. PMID: 42699247; PMCID: PMC13542932.

Tags: Hematology/Oncology, Publications

Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

Kishan AU, Zekster Y, Singer AE, Taparra K, Valle LF, Steinberg ML, Nickols NG, Reiter RE, Czernin J, Calais J, Lee JK, Hardesty LR, Rettig[...]

Divergent evolution in bilateral prostate cancer: a case study

Haas R, Huang RR, Weiner AB, Patel Y, Liu LY, Yamaguchi TN, Agrawal R, Boutros PC, Reiter RE. Divergent evolution in bilateral prostate cancer: a[...]

Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge

Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient[...]